Detection of the gene rearrangement in chronic myelogenous leukemia with biotinylated gene probes.
The breakpoint cluster region gene rearrangement associated with chronic myelogenous leukemia is becoming important in the diagnosis and management of the disease. At this time, the ability to demonstrate the gene rearrangement is limited to a few research laboratories. The problem results partially from unfamiliarity of medical laboratory personnel with DNA technology, but more because of the restricted use of radiolabeled phosphorus in hospital laboratories. With the introduction of biotinylated deoxynucleotides, nucleic acid hybridization procedures can now be performed without the use of radioisotopically labeled gene probes. This article describes the use of biotin-labeled gene probes to detect the gene rearrangement of the breakpoint cluster region of chromosome 22 in chronic myelogenous leukemia. The techniques are reproducible, sensitive, and safe. With the procedures described in this article, the assay can become more available to medical laboratories interested in offering this diagnostic and decision-making tool.
Tilzer
L L
LL
Department of Pathology, Kansas University Medical Center, Kansas City 66103.
Concepcion
E G
EG
D001710:Biotin / Q000031:analogs & derivatives*; D015139:Blotting, Southern; D002892:Chromosomes, Human, Pair 22 / Q000648:ultrastructure; D004247:DNA / Q000302:isolation & purification; D015342:DNA Probes; D003856:Deoxyuracil Nucleotides; D015321:Gene Rearrangement; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000235:genetics*; D009693:Nucleic Acid Hybridization; D010761:Phosphorus Radioisotopes
D015342:DNA Probes; D003856:Deoxyuracil Nucleotides; D010761:Phosphorus Radioisotopes; D001710:Biotin; C045931:biotin-11-dUTP; D004247:DNA